Patents Assigned to Chiesi Farmaceutici S.p.A.
  • THERAPEUTIC COMBINATION COMPRISING A PULMONARY SURFACTANT AND A STEROID FOR THE TREATMENT OF EVOLVING BPD
    Publication number: 20200246391
    Abstract: Administering a pulmonary surfactant and a corticosteroid is effective for the treatment of evolving bronchopulmonary dysplasia (BPD) in preterm neonates.
    Type: Application
    Filed: April 22, 2020
    Publication date: August 6, 2020
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Laura FABBRI, Fabrizio SALOMONE
  • PHARMACEUTICAL FORMULATIONS COMPRISING OPIOID RECEPTOR AGONIST AS ACTIVE INGREDIENTS, METHODS OF MANUFACTURE AND THERAPEUTIC USES THEREOF
    Publication number: 20200237650
    Abstract: Formulation comprising buprenorphine or a pharmaceutically acceptable salt thereof as the sole active ingredient, a viscosity enhancer, and a buffering agent in an amount to provide a pH of from 5.0 to 7.0 are useful for treating opioid withdrawal syndrome.
    Type: Application
    Filed: April 16, 2020
    Publication date: July 30, 2020
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Grazia CAIVANO, Ana Filipa SILVA BORGES
  • Carrier particles for dry powder formulations for inhalation
    Patent number: 10709666
    Abstract: Carrier particles in the form of granules described herein are suitable for use in dry powder formulations for inhalation, and preferably administering high-strength dose active ingredients.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: July 14, 2020
    Assignee: CHIESI FARMACEUTICI S.P.A.
    Inventors: Francesca Schiaretti, Francesca Buttini, Ruggero Bettini, Enrico Salomi, Andrea Benassi
  • Therapeutic combination comprising a pulmonary surfactant and a steroid for the treatment of evolving BPD
    Patent number: 10668110
    Abstract: Administering a pulmonary surfactant and a corticosteroid is effective for the treatment of evolving bronchopulmonary dysplasia (BPD) in preterm neonates.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: June 2, 2020
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Laura Fabbri, Fabrizio Salomone
  • NOVEL CARRIER PARTICLES FOR DRY POWDER FORMULATIONS FOR INHALATION
    Publication number: 20200163883
    Abstract: Carrier particles in the form of granules described herein are suitable for use in dry powder formulations for inhalation, and preferably administering high-strength dose active ingredients.
    Type: Application
    Filed: January 29, 2020
    Publication date: May 28, 2020
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Francesca Schiaretti, Francesca Buttini, Ruggero Bettini, Enrico Salomi, Andrea Benassi
  • Pharmaceutical formulations comprising opioid receptor agonist as active ingredients, methods of manufacture and therapeutic uses thereof
    Patent number: 10660849
    Abstract: Formulation comprising buprenorphine or a pharmaceutically acceptable salt thereof as the sole active ingredient, a viscosity enhancer, and a buffering agent in an amount to provide a pH of from 5.0 to 7.0 are useful for treating opioid withdrawal syndrome.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: May 26, 2020
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Grazia Caivano, Ana Filipa Silva Borges
  • Short-Acting Dihydropyridines (Clevidipine) For Use in Reducing Stroke Damage
    Publication number: 20200155528
    Abstract: The present invention relates to methods for lowering stroke damages and/or lowering blood pressure in a subject with a stroke in need thereof, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a short acting dihydropyridine compound, preferably clevidipine or a pharmaceutically acceptable salt or ester thereof. Also provided are related medicaments, pharmaceutical compositions, and methods for preparing the medicaments.
    Type: Application
    Filed: July 23, 2019
    Publication date: May 21, 2020
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventor: Gregory Charles WILLIAMS
  • CRYSTALLINE MICROPARTICLES OF A BETA-AGONIST COATED WITH A FATTY ACID
    Publication number: 20200138724
    Abstract: Crystalline microparticles consisting of a phenylalkylamino beta2-adrenergic agonist coated with a C12-C20 fatty acid are useful for the preparation of pharmaceutical aerosol formulations in form of suspension in a liquefied propellant gas or powder formulations.
    Type: Application
    Filed: January 9, 2020
    Publication date: May 7, 2020
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Gaetano BRAMBILLA, Paolo Colombo, Francesca Buttini, Michele Miozzi
  • Stable pressurized aerosol solution composition of glycopyrronium bromide and formoterol combination
    Patent number: 10617669
    Abstract: Aerosol solution compositions intended for use with a pressurized metered dose inhaler, comprising glycopyrronium bromide and formoterol, or a salt thereof, optionally in combination with one or more additional active ingredients, and stabilized by a selected amount of a mineral acid, exhibit improved stability when contained in an aerosol can provided with a metering valve having at least a butyl rubber gasket.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: April 14, 2020
    Assignee: CHIESI FARMACEUTICI S.P.A.
    Inventors: Sauro Bonelli, Diego Copelli, Massimiliano Dagli Alberi, Francesca Usberti, Enrico Zambelli
  • Stable pressurized aerosol solution composition of glycopyrronium bromide and formoterol combination
    Patent number: 10617638
    Abstract: Aerosol solution compositions intended for use with a pressurized metered dose inhaler, comprising glycopyrronium bromide and formoterol, or a salt thereof or a solvate of said salt, optionally in combination with one or more additional active ingredients, and stabilized by a selected amount of a mineral acid, exhibit improved stability when contained in a can internally coated by a resin comprising a fluorinated ethylene propylene (FEP) polymer.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: April 14, 2020
    Assignee: CHIESI FARMACEUTICI S.P.A.
    Inventors: Sauro Bonelli, Diego Copelli, Massimiliano Dagli Alberi, Francesca Usberti, Enrico Zambelli
  • Stable pressurized aerosol solution composition of glycopyrronium bromide and formoterol combination
    Patent number: 10596113
    Abstract: Aerosol solution compositions intended for use with a pressurized metered dose inhaler, comprising glycopyrronium bromide and formoterol, or a salt thereof or a solvate of said salt, optionally in combination with one or more additional active ingredients, and stabilized by a selected amount of a mineral acid, exhibit improved stability when contained in a can internally coated by a resin comprising a fluorinated ethylene propylene (FEP) polymer.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: March 24, 2020
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Sauro Bonelli, Diego Copelli, Massimiliano Dagli Alberi, Francesca Usberti, Enrico Zambelli
  • Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
    Patent number: 10596149
    Abstract: Aerosol solution compositions intended for use with a pressurized metered dose inhaler, comprising glycopyrronium bromide and formoterol, or a salt thereof, optionally in combination with one or more additional active ingredients, and stabilized by a selected amount of a mineral acid, exhibit improved stability when contained in an aerosol can provided with a metering valve having at least a butyl rubber gasket.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: March 24, 2020
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Sauro Bonelli, Diego Copelli, Massimiliano Dagli Alberi, Francesca Usberti, Enrico Zambelli
  • PHARMACEUTICAL SOLUTION FORMULATIONS FOR PRESSURISED METERED DOSE INHALERS
    Publication number: 20200085729
    Abstract: The invention relates to the prevention and/or treatment of a severe broncho-pulmonary disease by administering a solution formulation from a pressurized metered dose inhaler capable of providing therapeutical doses of two or more active drug substances to the lung, wherein all the active drug substances are fully dissolved in the formulation as well as the two or more active drug substances are delivered with substantially the same particle size distribution.
    Type: Application
    Filed: November 20, 2019
    Publication date: March 19, 2020
    Applicant: Chiesi Farmaceutici S.P.A.
    Inventors: David Andrew Lewis, Brian John Meakin, Gaetano Brambilla
  • TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS
    Publication number: 20200079774
    Abstract: Bicyclic dihydropyrimidine-carboxamide compounds of formula I described herein inhibit Rho Kinase and may be used for the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Application
    Filed: October 18, 2019
    Publication date: March 12, 2020
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Alessandro ACCETTA, Fabio RANCATI, Anna Maria CAPELLI, David Edward CLARK, Patrizia TISSELLI, Christine EDWARDS, Gurdip BHALAY, Arnaud Jean Francois Auquste CHEGUILLAUME
  • Bicyclic dihydropyrimidine-carboxamide derivatives as Rho-Kinase inhibitors
    Patent number: 10584128
    Abstract: Bicyclic dihydropyrimidine-carboxamide compounds of formula I described herein inhibit Rho Kinase and may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and pulmonary arterial hypertension (PAH).
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: March 10, 2020
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Alessandro Accetta, Fabio Rancati, Anna Maria Capelli, David Edward Clark, Patrizia Tisselli, Christine Edwards, Gurdip Bhalay
  • Carrier particles for dry powder formulations for inhalation
    Patent number: 10583085
    Abstract: Carrier particles in the form of granules described herein are suitable for use in dry powder formulations for inhalation, and preferably administering high-strength dose active ingredients.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: March 10, 2020
    Assignee: CHIESI FARMACEUTICI S.P.A.
    Inventors: Francesca Schiaretti, Francesca Buttini, Ruggero Bettini, Enrico Salomi, Andrea Benassi
  • METHOD OF PREVENTING OF SYSTEMIC-TO-PULMONARY-ARTERY SHUNT THROMBOSIS
    Publication number: 20200054662
    Abstract: The present invention is directed to the use of cangrelor for the treatment and/or prevention of shunt thrombosis in patients suffering congenital heart diseases undergoing shunt surgery. The invention is also directed to the use of cangrelor for the treatment and/or prevention of stent thrombosis in pediatric patients undergoing stent implantation.
    Type: Application
    Filed: June 22, 2018
    Publication date: February 20, 2020
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventor: Thomas Diacovo
  • Stable pharmaceutical formulation comprising a reconstituted pulmonary surfactant composition
    Patent number: 10543256
    Abstract: Physically and chemically stable pharmaceutical formulations in the form of an aqueous suspension comprising a reconstituted pulmonary surfactant are useful for the prophylaxis and/or treatment of respiratory distress syndrome (RDS) and other respiratory disorders.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: January 28, 2020
    Assignee: CHIESI FARMACEUTICI S.P.A.
    Inventors: Franco Sartor, Marisa Pertile, Annamaria Soliani Raschini
  • Pharmaceutical solution formulations for pressurised metered dose inhalers
    Patent number: 10525006
    Abstract: The invention relates to the prevention and/or treatment of a severe broncho-pulmonary disease by administering a solution formulation from a pressurized metered dose inhaler capable of providing therapeutical doses of two or more active drug substances to the lung, wherein all the active drug substances are fully dissolved in the formulation as well as the two or more active drug substances are delivered with substantially the same particle size distribution.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: January 7, 2020
    Assignee: CHIESI FARMACEUTICI S.P.A.
    Inventors: David Andrew Lewis, Brian John Meakin, Gaetano Brambilla
  • Tyrosine amide derivatives as Rho-kinase inhibitors
    Patent number: 10501461
    Abstract: Tyrosine amide compounds of formula I described herein inhibit Rho Kinase and may be used for the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: December 10, 2019
    Assignee: CHIESI FARMACEUTICI S.P.A.
    Inventors: Alessandro Accetta, Fabio Rancati, Anna Maria Capelli, David Edward Clark, Patrizia Tisselli, Christine Edwards, Gurdip Bhalay, Arnaud Jean Francois Auguste Cheguillaume